25 results
8-K
EX-10.1
NVTAQ
Invitae Corp
5 Jul 23
Departure of Directors or Certain Officers
4:53pm
that conflicts with this Agreement or otherwise creates a conflict of interest with Consultant’s Services.
10.Term; Termination. This Agreement is effective
PRE 14A
NVTAQ
Invitae Corp
4 Apr 22
Preliminary proxy
4:15pm
for potential conflict of interest situations on an ongoing basis and all such transactions relating to executive officers and directors must be approved by our
8-K
EX-10.1
v4d8of0zo13
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
8-K
EX-10.3
bp0gv
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-10.2
gvbuib1
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
425
hp2nr
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-10.1
i52zhcfyxnc78
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.3
2srerye
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-2.1
4ea tk1abx8j1uysp5
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.2
f0irbuhzzp jwg
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.2
dvij17rcvhhl2o
7 Nov 18
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume
4:14pm
10-K
4cd95qc g7idjhlcqu
30 Mar 15
Annual report
12:00am